Drug intelligence / Profile preview

IMC-3251

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IMC-3251 is a preclinical-stage Chimeric Antigen Receptor T-cell (CAR-T) therapy being developed by ImmuneCyte Life Sciences for the treatment of B-cell and T-cell lymphomas. The therapy involves the genetic engineering of T cells to express a chimeric receptor designed to recognize and eliminate malignant lymphoma cells. Currently in the preclinical or pilot phase, IMC-3251 is part of a pipeline focused on advancing cell-based immunotherapies for hematological cancers. While the specific target antigen has not been publicly detailed in high-level pipeline summaries, the program aims to address unmet needs in both B-cell and T-cell derived malignancies.

Other names: IMC-3251IMC3251IMC 3251

Beyond the preview

Go deeper on IMC-3251.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-3251.

Explore the full profile